People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Terumo Heart: Ann Arbor, Mich., subsidiary of the Japanese conglomerate names Thomas Gould as VP-clinical affairs and Mark Bullivant as director for international sales on Aug. 5, adding to the firms burgeoning left ventricular assist device unit. Gould comes from a VP of sales and marketing post at VentraAssist VAD developer Ventricor, which announced in March that it has run out of money. He will oversee Terumo's 140-patient U.S. pivotal trial for the DuraHeart ventricular assist device as a bridge-to-transplant (1"The Gray Sheet" April 13, 2009). Bullivant joins Terumo from St. Jude Medical's international cardiac surgery business and will focus on developing Terumo's international DuraHeart business, the company says
You may also be interested in...
Industry/Academia Advocacy Group Presses For Stable NIH Funding
United for Medical Research, a year-old advocacy organization that boasts BIO as a founding member, is bringing academic and industry groups together in a long-range effort to end the boom-or-bust funding cycles experienced by the National Institutes of Health
Industry/Academia Advocacy Group Presses For Stable NIH Funding
United for Medical Research, a year-old advocacy organization that boasts BIO as a founding member, is bringing academic and industry groups together in a long-range effort to end the boom-or-bust funding cycles experienced by the National Institutes of Health
Terumo Set To Build On Long-Term VAD Investments With Upcoming Trials
Terumo Corporation's long journey toward comercialization of the DuraHeart ventricular assist device is about to take a major step forward with the start of a U.S. "bridge-to-transplant" trial and the upcoming launch of a "destination therapy" trial